Pharmaceuticals, Biotechnology and Life Sciences
Basilea Pharmaceutica’s revenue grew of 31% for the full year, reaching CHF 133 million (€117M), the company said on Tuesday, noting it’s year-end cash position being at CHF 223 million.
Grupo Biotoscana has launched Basilea’s hospital antibiotic Zevtera (ceftobiprole) in Argentina, Basilea Pharmaceutica said Tuesday.
Basilea Pharmaceutica has entered into a license agreement with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. (CR Gosun) for Basilea’s antibiotic Zevtera (ceftobiprole) in China, Hong Kong and Macao (the Territory).